{"transactions":[{"id":2411,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":1825,"kind":"person","name":"Jolly Mohanjit","position":1,"cik":"0001867575","reported_name":"Jolly Mohanjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-03T20:30:05.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 1, 2026 the reporting person was granted an option to purchase 120,000 shares of the Issuer's common stock pursuant to the Issuer's 2025 Equity Incentive Plan. The shares subject to the option are fully vested."}],"balance_after":137833,"derivative":{"exercise_price":2.17,"expiration_date":"2036-09-01","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001213900-26-097218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1867575/000121390026097218/ownership.xml","form_type":"4"}},{"id":993624,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":72886,"kind":"person","name":"Pomichter Stanley D III","position":1,"cik":"0002085427","reported_name":"Pomichter Stanley D III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T21:10:06.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":17833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":17833,"derivative":{"exercise_price":0.66,"expiration_date":"2035-07-30","underlying":"Common Stock","underlying_shares":17833},"source":{"system":"sec-edgar","filing":"0001213900-25-112623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025112623/ownership.xml","form_type":"4"}},{"id":995550,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":1825,"kind":"person","name":"Jolly Mohanjit","position":1,"cik":"0001867575","reported_name":"Jolly Mohanjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T23:45:47.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":454456,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer."}],"balance_after":454456,"source":{"system":"sec-edgar","filing":"0001213900-25-112277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025112277/ownership.xml","form_type":"4"}},{"id":997675,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73061,"kind":"person","name":"Tincoff John M. III","position":1,"cik":"0002085876","reported_name":"Tincoff John M. III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T02:11:17.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":17833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":17833,"derivative":{"exercise_price":0.66,"expiration_date":"2035-07-30","underlying":"Common Stock","underlying_shares":17833},"source":{"system":"sec-edgar","filing":"0001213900-25-111711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025111711/ownership.xml","form_type":"4"}},{"id":997674,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73060,"kind":"person","name":"Sengupta Shiladitya","position":1,"cik":"0001604700","reported_name":"Sengupta Shiladitya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T00:36:39.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":624432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 624,432 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":624432,"derivative":{"exercise_price":0.66,"exercise_date":"2025-11-13","expiration_date":"2035-07-30","underlying":"Common Stock","underlying_shares":624432},"source":{"system":"sec-edgar","filing":"0001213900-25-111683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025111683/ownership.xml","form_type":"4"}},{"id":997672,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73059,"kind":"person","name":"Nelabhotla Venkateswarlu","position":1,"cik":"0002083546","reported_name":"Nelabhotla Venkateswarlu","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T00:35:03.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":615149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"security","element":"securityTitle","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement the reporting person was granted options to purchase 615,149 shares of the Issuer's common stock, all of which were fully vested as of the grant date. The options were granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":615149,"derivative":{"exercise_price":0.66,"exercise_date":"2025-11-13","expiration_date":"2035-07-30","underlying":"Common Stock","underlying_shares":615149},"source":{"system":"sec-edgar","filing":"0001213900-25-111681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025111681/ownership.xml","form_type":"4"}},{"id":1034429,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":73059,"kind":"person","name":"Nelabhotla Venkateswarlu","position":1,"cik":"0002083546","reported_name":"Nelabhotla Venkateswarlu","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-22T21:24:22.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."}],"balance_after":7,"source":{"system":"sec-edgar","filing":"0001213900-25-090188","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000121390025090188/ownership.xml","form_type":"4"}},{"id":1042748,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":75514,"kind":"person","name":"Dickey Robert IV","position":1,"cik":"0001466862","reported_name":"Dickey Robert IV","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-11T21:21:17.000Z","date":"2025-08-15","kind":"grant","planned":false,"acquired":true,"shares":762,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer (\"Merger Sub\"), and Vyome Therapeutics, Inc. (\"Vyome Therapeutics\"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the \"Merger\"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed \"Vyome Holdings, Inc.\" and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."}],"balance_after":762,"source":{"system":"sec-edgar","filing":"0001213900-25-086999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466862/000121390025086999/ownership.xml","form_type":"4"}},{"id":1434892,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-08-13T16:29:13.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":48,"price":0.25,"value":12.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":22777,"source":{"system":"sec-edgar","filing":"0001235802-24-000059","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580224000059/primary_doc.xml","form_type":"4"}},{"id":1434891,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-08-13T16:29:13.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":43,"price":0.17,"value":7.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":22825,"source":{"system":"sec-edgar","filing":"0001235802-24-000059","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580224000059/primary_doc.xml","form_type":"4"}},{"id":1434890,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-08-13T16:29:13.000Z","date":"2023-12-31","kind":"sale","planned":false,"acquired":false,"shares":42,"price":0.25,"value":10.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":22868,"source":{"system":"sec-edgar","filing":"0001235802-24-000059","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580224000059/primary_doc.xml","form_type":"4"}},{"id":1434889,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2024-08-13T16:29:13.000Z","date":"2023-11-30","kind":"sale","planned":false,"acquired":false,"shares":39,"price":0.23,"value":8.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":22910,"source":{"system":"sec-edgar","filing":"0001235802-24-000059","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580224000059/primary_doc.xml","form_type":"4"}},{"id":1746827,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-11-08T16:16:25.000Z","date":"2023-10-25","kind":"sale","planned":false,"acquired":false,"shares":131,"price":0.27,"value":35.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":22949,"source":{"system":"sec-edgar","filing":"0001235802-23-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000110/primary_doc.xml","form_type":"4"}},{"id":1746826,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-11-08T16:16:25.000Z","date":"2023-10-11","kind":"sale","planned":false,"acquired":false,"shares":39,"price":0.93,"value":36.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":23080,"source":{"system":"sec-edgar","filing":"0001235802-23-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000110/primary_doc.xml","form_type":"4"}},{"id":1746825,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-11-08T16:16:25.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":118,"price":0.89,"value":105.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":23119,"source":{"system":"sec-edgar","filing":"0001235802-23-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000110/primary_doc.xml","form_type":"4"}},{"id":1746824,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-11-08T16:16:25.000Z","date":"2023-08-24","kind":"sale","planned":false,"acquired":false,"shares":39,"price":1.42,"value":55.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":23237,"source":{"system":"sec-edgar","filing":"0001235802-23-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000110/primary_doc.xml","form_type":"4"}},{"id":1746823,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-11-08T16:16:25.000Z","date":"2023-08-04","kind":"sale","planned":false,"acquired":false,"shares":108,"price":1.43,"value":154.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":23276,"source":{"system":"sec-edgar","filing":"0001235802-23-000110","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000110/primary_doc.xml","form_type":"4"}},{"id":1826941,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-07-19T16:07:39.000Z","date":"2023-07-06","kind":"sale","planned":false,"acquired":false,"shares":106,"price":1.47,"value":155.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":23384,"source":{"system":"sec-edgar","filing":"0001235802-23-000077","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000077/primary_doc.xml","form_type":"4"}},{"id":1834016,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-07-06T16:16:26.000Z","date":"2023-06-30","kind":"purchase","planned":false,"acquired":true,"shares":17702,"price":1.52,"value":26907.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.54, inclusive.  The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":23490,"source":{"system":"sec-edgar","filing":"0001235802-23-000075","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000075/primary_doc.xml","form_type":"4"}},{"id":1834015,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-07-06T16:16:26.000Z","date":"2023-05-31","kind":"sale","planned":false,"acquired":false,"shares":98,"price":2.41,"value":236.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":5788,"source":{"system":"sec-edgar","filing":"0001235802-23-000075","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000075/primary_doc.xml","form_type":"4"}},{"id":1834014,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-07-06T16:16:26.000Z","date":"2023-04-30","kind":"sale","planned":false,"acquired":false,"shares":96,"price":2.36,"value":226.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":5886,"source":{"system":"sec-edgar","filing":"0001235802-23-000075","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000075/primary_doc.xml","form_type":"4"}},{"id":1834013,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-07-06T16:16:26.000Z","date":"2023-03-31","kind":"sale","planned":false,"acquired":false,"shares":109,"price":2.6,"value":283.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":5982,"source":{"system":"sec-edgar","filing":"0001235802-23-000075","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000075/primary_doc.xml","form_type":"4"}},{"id":1966216,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-07T16:11:11.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":103,"price":4.25,"value":437.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock."}],"balance_after":6091,"source":{"system":"sec-edgar","filing":"0001235802-23-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000030/primary_doc.xml","form_type":"4"}},{"id":1966215,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-07T16:11:11.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":157,"price":13.29,"value":2086.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock."}],"balance_after":6194,"source":{"system":"sec-edgar","filing":"0001235802-23-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000030/primary_doc.xml","form_type":"4"}},{"id":1966214,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-07T16:11:11.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":110,"price":7.4906,"value":823.966,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock."}],"balance_after":6351,"source":{"system":"sec-edgar","filing":"0001235802-23-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000030/primary_doc.xml","form_type":"4"}},{"id":1966213,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-07T16:11:11.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":48,"price":7.49,"value":359.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock."}],"balance_after":6461,"source":{"system":"sec-edgar","filing":"0001235802-23-000030","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580223000030/primary_doc.xml","form_type":"4"}},{"id":2079927,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-12-20T16:35:43.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":2213,"price":0.1509,"value":333.9417,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":325404,"source":{"system":"sec-edgar","filing":"0001235802-22-000136","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000136/primary_doc.xml","form_type":"4"}},{"id":2079926,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-12-20T16:35:43.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":5144,"price":0.1513,"value":778.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":327617,"source":{"system":"sec-edgar","filing":"0001235802-22-000136","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000136/primary_doc.xml","form_type":"4"}},{"id":2079925,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-12-20T16:35:43.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":364756,"price":0.1695,"value":61826.142,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were sold to cover taxes and fees in connection with the stock bonus."}],"balance_after":332761,"source":{"system":"sec-edgar","filing":"0001235802-22-000136","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000136/primary_doc.xml","form_type":"4"}},{"id":2079924,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-12-20T16:35:43.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":364756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were issued pursuant to a stock bonus granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":697517,"source":{"system":"sec-edgar","filing":"0001235802-22-000136","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000136/primary_doc.xml","form_type":"4"}},{"id":2120165,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-11-10T16:10:02.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":2510,"price":0.2724,"value":683.724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":332761,"source":{"system":"sec-edgar","filing":"0001235802-22-000119","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000119/primary_doc.xml","form_type":"4"}},{"id":2120164,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-11-10T16:10:02.000Z","date":"2022-11-04","kind":"sale","acquired":false,"shares":5883,"price":0.2725,"value":1603.1175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":335271,"source":{"system":"sec-edgar","filing":"0001235802-22-000119","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000119/primary_doc.xml","form_type":"4"}},{"id":2141366,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-10-06T17:29:35.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":2484,"price":0.2812,"value":698.5008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":338670,"source":{"system":"sec-edgar","filing":"0001235802-22-000112","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000112/primary_doc.xml","form_type":"4"}},{"id":2141365,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-10-06T17:29:35.000Z","date":"2022-10-04","kind":"sale","acquired":false,"shares":5809,"price":0.2807,"value":1630.5863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":341154,"source":{"system":"sec-edgar","filing":"0001235802-22-000112","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000112/primary_doc.xml","form_type":"4"}},{"id":2161331,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-09-12T16:05:32.000Z","date":"2022-09-06","kind":"sale","acquired":false,"shares":4828,"price":0.39,"value":1882.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":346963,"source":{"system":"sec-edgar","filing":"0001235802-22-000109","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000109/primary_doc.xml","form_type":"4"}},{"id":2188014,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-08-11T20:15:08.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":11674,"price":0.47,"value":5486.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":773098,"source":{"system":"sec-edgar","filing":"0001235802-22-000091","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000091/primary_doc.xml","form_type":"4"}},{"id":2188230,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-08-11T16:30:45.000Z","date":"2022-08-05","kind":"sale","acquired":false,"shares":4728,"price":0.47,"value":2222.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":351791,"source":{"system":"sec-edgar","filing":"0001235802-22-000092","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000092/primary_doc.xml","form_type":"4"}},{"id":2211752,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-07-06T20:03:12.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":11442,"price":0.55,"value":6293.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":784772,"source":{"system":"sec-edgar","filing":"0001235802-22-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000080/primary_doc.xml","form_type":"4"}},{"id":2212123,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-07-06T16:08:29.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":4630,"price":0.55,"value":2546.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":356519,"source":{"system":"sec-edgar","filing":"0001235802-22-000081","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000081/primary_doc.xml","form_type":"4"}},{"id":2242195,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-06T20:58:30.000Z","date":"2022-06-01","kind":"sale","acquired":false,"shares":2699,"price":0.96,"value":2591.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":796214,"source":{"system":"sec-edgar","filing":"0001235802-22-000078","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000078/primary_doc.xml","form_type":"4"}},{"id":2242194,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-06T20:58:30.000Z","date":"2022-06-01","kind":"sale","acquired":false,"shares":8610,"price":0.95,"value":8179.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":798913,"source":{"system":"sec-edgar","filing":"0001235802-22-000078","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000078/primary_doc.xml","form_type":"4"}},{"id":2242537,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-06T16:49:54.000Z","date":"2022-06-01","kind":"sale","acquired":false,"shares":4478,"price":0.96,"value":4298.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":361149,"source":{"system":"sec-edgar","filing":"0001235802-22-000077","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000077/primary_doc.xml","form_type":"4"}},{"id":2249650,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":1228,"price":0.95,"value":1166.6,"ownership":{"direct":true},"balance_after":365627,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249649,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":6539,"price":0.94,"value":6146.66,"ownership":{"direct":true},"balance_after":364399,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249648,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":60,"price":0.93,"value":55.8,"ownership":{"direct":true},"balance_after":357860,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249647,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":7995,"price":0.92,"value":7355.4,"ownership":{"direct":true},"balance_after":357800,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249646,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":1000,"price":0.9,"value":900.0,"ownership":{"direct":true},"balance_after":349805,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249645,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":200,"price":0.89,"value":178.0,"ownership":{"direct":true},"balance_after":348805,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249644,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":2900,"price":0.88,"value":2552.0,"ownership":{"direct":true},"balance_after":348605,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2249643,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-06-01T14:18:18.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":78,"price":0.87,"value":67.86,"ownership":{"direct":true},"balance_after":345705,"source":{"system":"sec-edgar","filing":"0001104659-22-067045","document":"tm2217476-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000110465922067045/tm2217476-1_4seq1.xml","form_type":"4"}},{"id":2273394,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-05-12T20:13:38.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":11417,"price":0.77,"value":8791.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":807523,"source":{"system":"sec-edgar","filing":"0001235802-22-000059","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000059/primary_doc.xml","form_type":"4"}},{"id":2273591,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-05-12T16:05:18.000Z","date":"2022-05-05","kind":"sale","acquired":false,"shares":4529,"price":0.77,"value":3487.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":345627,"source":{"system":"sec-edgar","filing":"0001235802-22-000058","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000058/primary_doc.xml","form_type":"4"}},{"id":2300158,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-04-08T20:12:04.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":11063,"price":1.13,"value":12501.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":818940,"source":{"system":"sec-edgar","filing":"0001235802-22-000044","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000044/primary_doc.xml","form_type":"4"}},{"id":2300406,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-04-08T16:27:26.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":5038,"price":1.13,"value":5692.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":350156,"source":{"system":"sec-edgar","filing":"0001235802-22-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000045/primary_doc.xml","form_type":"4"}},{"id":2360309,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-03-02T21:08:32.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":6538,"price":1.06,"value":6930.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":830003,"source":{"system":"sec-edgar","filing":"0001235802-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000034/primary_doc.xml","form_type":"4"}},{"id":2361114,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-03-02T16:15:19.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":3658,"price":1.06,"value":3877.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":355194,"source":{"system":"sec-edgar","filing":"0001235802-22-000035","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000035/primary_doc.xml","form_type":"4"}},{"id":2416315,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-02-02T21:32:03.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":8324,"price":1.22,"value":10155.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":836541,"source":{"system":"sec-edgar","filing":"0001235802-22-000022","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000022/primary_doc.xml","form_type":"4"}},{"id":2416927,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-02-02T16:22:30.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":3684,"price":1.22,"value":4494.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":358852,"source":{"system":"sec-edgar","filing":"0001235802-22-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000021/primary_doc.xml","form_type":"4"}},{"id":2422429,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-01-28T21:58:12.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":7150,"price":1.79,"value":12798.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":844865,"source":{"system":"sec-edgar","filing":"0001235802-22-000020","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580222000020/primary_doc.xml","form_type":"4"}},{"id":2422634,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2022-01-28T16:46:32.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":3171,"price":1.78,"value":5644.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 22, 2021, Mr. Stankovich was awarded an aggregate of 372,744 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021.  The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units."}],"balance_after":362536,"source":{"system":"sec-edgar","filing":"0001235802-22-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580222000019/primary_doc.xml","form_type":"4"}},{"id":2478864,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-12-09T21:22:04.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":13427,"price":1.83,"value":24571.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":852015,"source":{"system":"sec-edgar","filing":"0001235802-21-000141","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580221000141/primary_doc.xml","form_type":"4"}},{"id":2479031,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-12-09T16:17:33.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":4304,"price":1.827,"value":7863.408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $1.82 to $1.83, inclusive.  The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":365707,"source":{"system":"sec-edgar","filing":"0001235802-21-000140","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000140/primary_doc.xml","form_type":"4"}},{"id":2505019,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-11-18T16:32:09.000Z","date":"2021-11-18","kind":"purchase","acquired":true,"shares":20000,"price":2.02,"value":40400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.05, inclusive.  The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":370011,"source":{"system":"sec-edgar","filing":"0001235802-21-000132","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000132/primary_doc.xml","form_type":"4"}},{"id":2510454,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-11-16T21:18:50.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":13505,"price":2.69,"value":36328.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":865442,"source":{"system":"sec-edgar","filing":"0001235802-21-000131","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580221000131/primary_doc.xml","form_type":"4"}},{"id":2510859,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-11-16T16:14:25.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":4320,"price":2.69,"value":11620.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)\tThese shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":350011,"source":{"system":"sec-edgar","filing":"0001235802-21-000130","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000130/primary_doc.xml","form_type":"4"}},{"id":2544375,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-10-12T23:35:44.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":12565,"price":2.77,"value":34805.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":878947,"source":{"system":"sec-edgar","filing":"0001235802-21-000127","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000123580221000127/primary_doc.xml","form_type":"4"}},{"id":2544567,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-10-12T19:40:01.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":3660,"price":2.76,"value":10101.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":354331,"source":{"system":"sec-edgar","filing":"0001235802-21-000128","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000128/primary_doc.xml","form_type":"4"}},{"id":2565519,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T23:07:03.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":294494,"price":2.89,"value":851087.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."}],"balance_after":891512,"source":{"system":"sec-edgar","filing":"0001790300-21-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000011/primary_doc.xml","form_type":"4"}},{"id":2565518,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T23:07:03.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":225906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":1186006,"source":{"system":"sec-edgar","filing":"0001790300-21-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000011/primary_doc.xml","form_type":"4"}},{"id":2565517,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":124669,"kind":"person","name":"Bandy Barton P.","position":1,"cik":"0001773309","reported_name":"Bandy Barton P.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T23:07:03.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":960100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 480,050 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":960100,"source":{"system":"sec-edgar","filing":"0001790300-21-000011","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000011/primary_doc.xml","form_type":"4"}},{"id":2565516,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":135382,"kind":"person","name":"GLADNEY DAN W","position":1,"cik":"0001224184","reported_name":"GLADNEY DAN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T22:37:24.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":200000,"price":2.99,"value":598000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"A portion of these shares were sold to cover taxes in connection with the vesting of restricted stock units."}],"balance_after":283922,"source":{"system":"sec-edgar","filing":"0001790300-21-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000009/primary_doc.xml","form_type":"4"}},{"id":2565515,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":135382,"kind":"person","name":"GLADNEY DAN W","position":1,"cik":"0001224184","reported_name":"GLADNEY DAN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T22:37:24.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":483922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":483922,"source":{"system":"sec-edgar","filing":"0001790300-21-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000009/primary_doc.xml","form_type":"4"}},{"id":2566374,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":28335,"kind":"person","name":"BLACKFORD GARY","position":1,"cik":"0001156320","reported_name":"BLACKFORD GARY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T22:25:54.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":253429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":253429,"source":{"system":"sec-edgar","filing":"0001790300-21-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1156320/000179030021000008/primary_doc.xml","form_type":"4"}},{"id":2565514,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":135381,"kind":"person","name":"MINOCHERHOMJEE ARDA PHD","position":1,"cik":"0001288238","reported_name":"MINOCHERHOMJEE ARDA PHD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T22:18:00.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":253429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":253429,"source":{"system":"sec-edgar","filing":"0001790300-21-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000179030021000007/primary_doc.xml","form_type":"4"}},{"id":2566053,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T18:51:57.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":48366,"price":2.89,"value":139777.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares were sold to cover taxes in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4."}],"balance_after":357991,"source":{"system":"sec-edgar","filing":"0001790300-21-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000179030021000010/primary_doc.xml","form_type":"4"}},{"id":2566052,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T18:51:57.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":90362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":406357,"source":{"system":"sec-edgar","filing":"0001790300-21-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000179030021000010/primary_doc.xml","form_type":"4"}},{"id":2566051,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T18:51:57.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":282382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":315995,"source":{"system":"sec-edgar","filing":"0001790300-21-000010","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000179030021000010/primary_doc.xml","form_type":"4"}},{"id":2565786,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":135386,"kind":"person","name":"McDougal Lori Courtney","position":1,"cik":"0001649837","reported_name":"McDougal Lori Courtney","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-09-17T18:07:14.000Z","date":"2021-07-22","kind":"grant","acquired":true,"shares":253429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan."}],"balance_after":253429,"source":{"system":"sec-edgar","filing":"0001790300-21-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649837/000179030021000006/primary_doc.xml","form_type":"4"}},{"id":2585247,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-08-31T16:31:05.000Z","date":"2021-08-30","kind":"purchase","acquired":true,"shares":15000,"price":3.429,"value":51435.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"(1)\tThe price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.46, inclusive.  The reporting person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":32613,"source":{"system":"sec-edgar","filing":"0001235802-21-000116","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000116/primary_doc.xml","form_type":"4"}},{"id":2592454,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":88345,"kind":"person","name":"STANKOVICH THOMAS","position":1,"cik":"0001181166","reported_name":"STANKOVICH THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.001 par value per share","published_at":"2021-08-24T08:59:19.000Z","date":"2021-08-20","kind":"purchase","acquired":true,"shares":15000,"price":3.219,"value":48285.0,"ownership":{"direct":true},"balance_after":17613,"source":{"system":"sec-edgar","filing":"0001235802-21-000111","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181166/000123580221000111/primary_doc.xml","form_type":"4"}},{"id":2651603,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651602,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":563700,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":563700},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651601,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651600,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":2254800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2254800},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651599,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651598,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":676440},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651597,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651596,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":676440},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651595,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651594,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1479713},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651593,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651592,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1479713},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651591,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":7223346,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651590,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":563700,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7223346,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651589,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":6659646,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651588,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":2254800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6659646,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651587,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":4404846,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651586,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4404846,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651585,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":3728406,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651584,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3728406,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}}],"next_cursor":"2021-06-30T01:44:48.000000Z,2651584"}